Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Genprex Inc (NQ: GNPX ) 0.3576 -0.0041 (-1.13%) Streaming Delayed Price Updated: 9:30 AM EDT, Oct 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Genprex Inc < Previous 1 2 3 4 5 6 7 Next > InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures New Patent, Critical Protection for REQORSA(TM) Combination Therapy August 16, 2022 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Product Safety This Financial Services Stock Surged Around 116%; Here Are 86 Biggest Movers From Yesterday August 16, 2022 Gainers Magic Empire Global Limited (NASDAQ: MEGL) shares jumped 115.7% to close at $17.73 on volatility following the company's IPO earlier this month. Via Benzinga Recap Of Monday's Biotech Catalysts - End Of the Day Summary August 15, 2022 Via Benzinga Why Viridian Therapeutics Is Trading Higher By Around 58%, Here Are 67 Stocks Moving In Monday's Mid-Day Session August 15, 2022 Gainers Sunrise New Energy Co. Ltd. (NASDAQ: EPOW) shares jumped 118.2% to $4.4948. Sunrise New Energy said that the company changed its name from Global Internet of the People, Inc. to Sunrise New... Via Benzinga InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures SRC Approval to Advance Acclaim-1 Trial to Higher Dose August 15, 2022 Via Investor Brand Network Exposures Product Safety InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate in Next Generation Lipid-Based Nanoparticles Delivery Summit July 13, 2022 Via Investor Brand Network Exposures Product Safety InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate in June Investor Conferences June 02, 2022 Via Investor Brand Network Exposures Product Safety InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Upcoming Investor Conference May 19, 2022 Via Investor Brand Network Exposures Product Safety InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) CMO to Participate at 33rd Annual Cancer Progress Conference as Expert Panelist May 09, 2022 Via Investor Brand Network Exposures Product Safety InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Shareholder Letter, 2022 Corporate Update May 05, 2022 Via Investor Brand Network Exposures Product Safety 12 Health Care Stocks Moving In Tuesday's Pre-Market Session May 03, 2022 Via Benzinga InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation in April 2022 Conferences April 18, 2022 Via Investor Brand Network InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Opens Acclaim-2 Clinical Trial for Patient Enrollment March 31, 2022 Via Investor Brand Network Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancer March 31, 2022 From Genprex, Inc. Via Business Wire InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at 2022 BIO Europe Spring Investor Conference March 23, 2022 Via Investor Brand Network Genprex to Participate in Upcoming Investor Conference in March March 23, 2022 From Genprex, Inc. Via Business Wire InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Dosing of First Patient in Acclaim-1 Clinical Trial March 02, 2022 Via Investor Brand Network InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate at February Investor Conferences February 09, 2022 Via Investor Brand Network Genprex to Present at Upcoming Investor Conferences Highlighting its Gene Therapies for Cancer and Diabetes February 09, 2022 From Genprex, Inc. Via Business Wire InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Positioned to Expand Oncology Programs, Further Explore Use of ONCOPREX(R) Nanoparticle Delivery System January 27, 2022 Via Investor Brand Network Preclinical Data Show Potential for Use of Genprex’s ONCOPREX® Nanoparticle Delivery System in Treating Colon Cancer January 27, 2022 From Genprex, Inc. Via Business Wire 18 Stocks Moving in Wednesday's Pre-Market Session January 26, 2022 Gainers Exicure, Inc. (NASDAQ: XCUR) rose 41.1% to $0.23 in pre-market trading after gaining around 4% on Tuesday. Barfresh Food Group, Inc. (NASDAQ: BRFH) shares rose 31.7% to $... Via Benzinga 48 Biggest Movers From Yesterday January 14, 2022 Gainers Singularity Future Technology Ltd. (NASDAQ: SGLY) shares rose 25.9% to settle at $5.01 on Thursday. MedAvail Holdings, Inc (NASDAQ: MDVL) gained 24.4% to settle at $1.58... Via Benzinga InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Accelerate Opening of Acclaim-1 Clinical Trial Sites January 10, 2022 Via Investor Brand Network Genprex to Accelerate Opening of Acclaim-1 Clinical Trial Sites for REQORSA™ Systemic Gene Therapy in Non-Small Cell Lung Cancer January 10, 2022 From Genprex, Inc. Via Business Wire 50 Biggest Movers From Yesterday January 06, 2022 Gainers Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) shares surged 63.7% to settle at $2.21 on Wednesday after the company announced that in preclinical studies its lead... Via Benzinga 12 Health Care Stocks Moving In Wednesday's Intraday Session January 05, 2022 Gainers Lixte Biotech Holdings (NASDAQ:LIXT) stock increased by 70.4% to $2.3 during Wednesday's regular session. Trading volume for this security as of 12:31 EST is... Via Benzinga 34 Stocks Moving In Wednesday's Mid-Day Session January 05, 2022 Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 49.7% to $15.45 after the company announced it acquired exclusive rights to novel mRNA biomarkers. Data Storage... Via Benzinga Genprex to Participate in January Investor and Healthcare Conferences to Highlight Company’s Gene Therapies in Cancer and Diabetes January 05, 2022 From Genprex, Inc. Via Business Wire 45 Biggest Movers From Yesterday January 05, 2022 Gainers ATA Creativity Global (NASDAQ: AACG) gained 114.3% to close at $2.55. Hoth Therapeutics, Inc. (NASDAQ: HOTH) surged 85.7% to settle at $1.30 after the company announced... Via Benzinga < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.